Penalty Amount
$300,000
Connecticut Attorney General William Tong announced a settlement with international trade platform Made-in-China to cease all U.S. sales of unlawful 'research grade' GLP-1 weight loss drugs following an investigation into direct sales to consumers without prescriptions or medical oversight. The settlement prohibits the platform from hosting GLP-1 sales to U.S. customers, requires a monitoring system to remove non-compliant listings, and imposes a $300,000 penalty suspended after an initial $30,000 payment. Additional settlements were announced with Radiance Medspa and Advanced Medical Weight Loss over compounded non-FDA approved GLP-1 drugs.
Made-in-China must prohibit manufacturers from advertising or selling GLP-1s to U.S. customers, deploy a monitoring system to detect and remove such listings, and remove existing GLP-1 listings within five days. The company is subject to a $300,000 penalty, with $30,000 due initially and the remaining $270,000 suspended; additional penalties apply for settlement violations.
In-house legal teams at online trade platforms and e-commerce vendors should review vendor agreements and terms of service to add explicit prohibitions on selling unapproved FDA-regulated drugs, prescription-only medications, and misbranded health products without valid medical oversight. Contracts should include requirements for automated monitoring systems to detect non-compliant listings, specified timeframes for removing prohibited content, and penalty clauses with suspended amounts that trigger upon breach of terms. Platforms should also include indemnification provisions and audit rights to ensure vendor compliance with health and safety regulations.
Entity
Made-in-China
Industry
Other"05/06/2026"
"Made-in-China"
"$300,000 penalty to the state, suspended after $30,000"
"violations of the Connecticut Unfair Trade Practices Act"
"unlawful sales of bootleg GLP-1 weight loss drugs direct to Connecticut consumers without prescriptions or any medical oversight"
"prohibits manufacturers from using the platform to advertise or sell GLP-1s to customers in the United States"
Attorney General Tong joined a coalition of 17 attorneys general in sending letters to the Office of the Comptroller of the Currency and the Federal Reserve Board, urging them to deny Opportunity Financial's application to acquire BNC National Bank. The merger would grant OppFi a national bank charter, allowing it to circumvent state lending laws and charge triple-digit interest rates, posing risks to consumers and the banking system.
The court granted the States' motion finding that Nexstar violated the preliminary injunction by placing current or former Nexstar executives on TEGNA's Board of Directors. The court ordered regular reporting to the States and appointed a special master to oversee compliance.
Attorney General William Tong co-led a coalition of 34 attorneys general in a letter to congressional leaders urging them to preserve the federal redefinition of hemp and reject efforts to weaken reforms addressing intoxicating hemp-derived products. The coalition warns that reopening the loophole would create regulatory uncertainty, compromise public safety, and allow unregulated intoxicating hemp products to return to the marketplace.
$400.0M
Minnesota Attorney General Keith Ellison joined a coalition of 43 states and territories in announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer engaged in conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for numerous generic prescription drugs. Sandoz will pay approximately $469 million total including prior settlements, and has agreed to injunctive terms and internal reforms.
Attorney General William Tong joined a coalition of 23 states and the District of Columbia in suing the Trump administration over policy changes by the Administration for Children and Families (ACF) that would allow broad sharing of TANF recipients' sensitive personal data across federal agencies and potentially private organizations. The lawsuit alleges violations of the Administrative Procedure Act and the Spending Clause, seeking to block the policy.
$400.0M
Attorney General Tong led a coalition of 43 states and territories in announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer engaged in conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade. Sandoz will pay approximately $469 million total and implement internal reforms to ensure fair competition and compliance with antitrust laws.